Allogene Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Allogene Therapeutics, Inc. (ALLO) reported Earnings Per Share, Basic and Diluted of -$1.89 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-02-23
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.25.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$1.04.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.52.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.53.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.89.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$2.08.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$1.83.
- Allogene Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$7.31.
| Period end | Earnings Per Share, Basic and Diluted 1 month | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | -$1.89 10-K · filed 2022-02-23 | ||||
| 2021-03-31 | -$0.25 10-Q · filed 2021-05-05 | -$1.28 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.80 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.34 derived: net income ÷ weighted average shares · filed 2024-03-14 | |
| 2020-12-31 | -$1.04 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.56 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.11 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.08 10-K · filed 2022-02-23 | |
| 2020-09-30 | -$0.52 10-Q · filed 2020-11-04 | -$1.05 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.55 10-Q · filed 2020-11-04 | -$2.13 derived: net income ÷ weighted average shares · filed 2022-02-23 | |
| 2020-06-30 | -$0.53 10-Q · filed 2020-08-05 | -$1.03 10-Q · filed 2020-08-05 | -$1.61 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$2.11 derived: net income ÷ weighted average shares · filed 2022-02-23 | |
| 2020-03-31 | -$0.50 10-Q · filed 2021-05-05 | -$1.08 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$1.58 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$2.00 derived: net income ÷ weighted average shares · filed 2022-02-23 | |
| 2019-12-31 | -$0.58 10-K · filed 2020-02-27 | -$1.08 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$1.50 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$1.83 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$0.50 10-Q · filed 2020-11-04 | -$0.91 derived: net income ÷ weighted average shares · filed 2020-11-04 | -$1.24 10-Q · filed 2020-11-04 | -$1.61 derived: net income ÷ weighted average shares · filed 2021-02-25 | |
| 2019-06-30 | -$0.41 10-Q · filed 2020-08-05 | -$0.74 10-Q · filed 2020-08-05 | -$1.11 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$2.07 derived: net income ÷ weighted average shares · filed 2021-02-25 | |
| 2019-03-31 | -$0.32 10-Q · filed 2020-05-06 | -$0.69 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.72 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$5.14 derived: net income ÷ weighted average shares · filed 2021-02-25 | |
| 2018-12-31 | -$0.37 10-K · filed 2020-02-27 | -$1.71 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$6.98 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$7.31 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$10.71 10-K · filed 2020-02-27 | -$49.98 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$16.38 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | -$43.82 10-K · filed 2020-02-27 | -$9.42 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | -$0.10 10-K · filed 2020-02-27 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |